Koichi Ito

Koichi Ito has extensive work experience in the field of biology and cancer research. Koichi is currently working at Prelude Therapeutics as the Director of Biology, a position they have held since August 2022. Prior to this role, they served as an Associate Director from April 2021 to July 2022. Before joining Prelude Therapeutics, Koichi worked as a Senior Research Scientist from April 2020 to March 2021 and as a Research Scientist from October 2018 to March 2020 at the same company.

Before their tenure at Prelude Therapeutics, Koichi worked as a Postdoctoral Research Fellow at the Icahn School of Medicine at Mount Sinai from August 2013 to September 2018. During this time, they conducted pre-clinical and translational studies to develop cancer therapeutics, focusing on breast cancer. Koichi identified new drug targets and investigated mechanisms related to chemotherapy resistance and immune microenvironment suppression.

Koichi also served as a Postdoctoral Research Staff at Columbia University Medical Center from December 2012 to July 2013, where they studied drug resistance mechanisms in melanoma.

In addition to their postdoctoral research roles, Koichi worked as a Research Assistant (Flow Cytometry Analyst) at Griffith University from July 2011 to October 2012, focusing on flow cytometry analysis.

Earlier in their career, they worked as a Research Staff at Kobe Pharmaceutical University from April 2007 to March 2008, where they evaluated the effects of Maitake beta-glucan on immune-stimulation and tumor growth.

Overall, Koichi Ito's work experience spans from various research positions, primarily in the fields of cancer therapeutics, immune microenvironment, and drug resistance mechanisms.

Koichi Ito's education history begins with their Bachelor of Pharmacy degree from Kobe Pharmaceutical University, which they obtained from 2003 to 2007. Later, they pursued a Doctor of Philosophy (PhD) degree in Cancer Biology and Cancer Immunology from Griffith University from 2009 to 2013.